Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18551050 | 0.85 | MTNR1A (0.47) | MTNR1AMTNR1BACHE | |
| SCHEMBL20324995 | 0.82 | CYP2D6 (0.49) | — | |
| SCHEMBL20443306 | 0.82 | CYP4F2 (0.38) | MTNR1AMTNR1BFFAR4 | |
| SCHEMBL21472028 | 0.82 | CYP4F2 (0.38) | MTNR1AMTNR1BFFAR4 | |
| SCHEMBL19176857 | 0.79 | HDAC1 (0.55) | MTNR1AMTNR1B | |
| SCHEMBL20133262 | 0.79 | MTNR1B (0.38) | MTNR1AMTNR1B | |
| SCHEMBL13295868 | 0.78 | CYP3A4 (0.50) | MTNR1AMTNR1BACHEFFAR4 | |
| SCHEMBL22527260 | 0.77 | CYP2D6 (0.54) | — | |
| SCHEMBL20372781 | 0.77 | KDM4E (0.53) | ACHE | |
| SCHEMBL9352820 | 0.77 | FFAR1 (0.55) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | YALE UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | YALE UNIVERSITY | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | BTK, CBL, CRBN | MTNR1A 3825/4885MTNR1B 2958/4885ACHE 2592/4885 |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | MTNR1A 3825/4885MTNR1B 2958/4885ACHE 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.